高级检索
当前位置: 首页 > 详情页

LH level on ovulation trigger day has a different impact on the outcomes of agonist and antagonist regimens during in vitro fertilization

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Reproductive Medicine, The First People’s Hospital of YunnanProvince, Kunming, China [2]Reproductive Medical Center of Yunnan Province,The Affiliated Hospital of Kunming University of Science and Technology, Kunming,China [3]NHC Key Laboratory of Periconception Health Birth in WesternChina, Kunming, China [4]Faculty of Life Science and Technology, Kunming Universityof Science and Technology, Kunming, China [5]Medical School, KunmingUniversity of Science and Technology, Kunming, China
出处:
ISSN:

关键词: Luteinizing hormone Assisted reproductive technology Clinical outcome Clinical pregnancy Live birth

摘要:
To assess the impact of the luteinizing hormone level on ovulation trigger day (LHOTD) on in vitro fertilization (IVF) outcomes in gonadotropin-releasing hormone (GnRH) agonist and antagonist regimens during fresh embryo transfer cycles.A stepwise, progressive multivariate regression model was introduced to assess the effect of the LHOTD on clinical pregnancy and live birth rates. Mantel‒Haenszel stratification analysis was used to examine the association between the LHOTD and clinical outcomes with the antagonist regimen.The LHOTD had different distributions in the agonist and antagonist regimens. The cycles were assigned into three LHOTD tertile groups. In the agonist regimen, compared with the 1st tertile (T1), in the 2nd (T2) and 3rd (T3) tertiles, the adjusted odds ratios (ORs) (95% confidence intervals [CIs], P value) were 1.187 (1.047-1.345, 0.007) and 1.420 (1.252-1.610, < 0.001) for clinical pregnancy, respectively, and 1.149 (1.009-1.309, 0.036) and 1.476 (1.296-1.681, < 0.001) for live birth. In the antagonist regimen, there was no significant difference in clinical pregnancy and live birth rates among the tertiles. However, in the stratified group of patients aged less than 35 years, the ORs (95% CIs, P value) of T2 and T3 were 1.316 (1.051-1.648, 0.017) and 1.354 (1.077-1.703, 0.009) for clinical pregnancy, respectively, and 1.275 (1.008-1.611, 0.043) and1.269 (0.999-1.611, 0.051) for live birth. Moreover, there was a discrepancy in the results among the subdivided LHOTD T1 groups adopting the antagonist regimen. Compared with that of the < 1.06 mIU/mL subgroup, the ORs (95% CIs, P value) of the > 1.5 mIU/mL subgroup were 1.693 (1.194-2.400, 0.003) for clinical pregnancy and 1.532 (1.057-2.220, 0.024) for live birth after eliminating potential confounders.The LHOTD was profoundly suppressed in the agonist regimen, and its level was positively correlated with clinical pregnancy and live birth rates. In contrast, in the flexible antagonist regimen, the LHOTD was significantly higher than that in the agonist regimen and did not correlate with the outcome, except for women in the nonadvanced age group and those with an excessively suppressed LHOTD. Further investigation is required to determine the rationale for these findings.© 2023. The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 生殖生物学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 生殖生物学
JCR分区:
出版当年[2022]版:
Q1 REPRODUCTIVE BIOLOGY
最新[2023]版:
Q1 REPRODUCTIVE BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Reproductive Medicine, The First People’s Hospital of YunnanProvince, Kunming, China [2]Reproductive Medical Center of Yunnan Province,The Affiliated Hospital of Kunming University of Science and Technology, Kunming,China [3]NHC Key Laboratory of Periconception Health Birth in WesternChina, Kunming, China [4]Faculty of Life Science and Technology, Kunming Universityof Science and Technology, Kunming, China [5]Medical School, KunmingUniversity of Science and Technology, Kunming, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Reproductive Medicine, The First People’s Hospital of YunnanProvince, Kunming, China [2]Reproductive Medical Center of Yunnan Province,The Affiliated Hospital of Kunming University of Science and Technology, Kunming,China [3]NHC Key Laboratory of Periconception Health Birth in WesternChina, Kunming, China [4]Faculty of Life Science and Technology, Kunming Universityof Science and Technology, Kunming, China [5]Medical School, KunmingUniversity of Science and Technology, Kunming, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82479 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号